Search PubMed⌕ Search

Biomedical subjects

J C Somberg

Publications and source records attributed to J C Somberg.

At least 19 recordsLinked to original sources
PubMed1995

Can nitroglycerin convert effort-induced angina in men into silent myocardial ischemia?

The relief of anginal pain with nitroglycerin may not correspond to the disappearance of ischemia. To evaluate the possible lack of the elimination of ischemia with sublingual nitroglycerin, we studied 25 male patients with stable angina pectoris who underwent exercise stress testing with recording of blood pressure, pulse, and ST-segment displacement. The stress test was repeated 30 minutes after administration of 0.4 mg of sublingual nitroglycerin. All 25 patients had angina and ischemic ST-segment changes in the first stress test. On repeat stress testing, 15 patients had angina and ST-segment changes, 2 patients had angina but no ST-segment changes, and 4 patients had no ST-segment changes and no angina. Four patients, however, had no angina but persistent ischemic ST-segment changes suggesting that angina was converted into silent ischemia. The mean exercise duration was 311 +/- 66 seconds before and 421 +/- 81 seconds after the nitroglycerin test. Peak heart rate and systolic blood pressure before the nitroglycerin stress test were 109 +/- 18 and 155 +/- 23 mm Hg; in the repeat stress test, they increased to 123 +/- 21 and 162 +/- 20 mm Hg, respectively.

Administration, Sublingual↗
PubMed1993

Branded generics.

Explore the source record for details and available documents.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1993

New FDA initiatives.

Explore the source record for details and available documents.

Adverse Drug Reaction Reporting Systems↗
PubMed1993

Proarrhythmia of nonantiarrhythmic drugs.

Proarrhythmic effects of nonantiarrhythmic drugs have not been as extensively studied or reported compared with the effects of antiarrhythmic drugs. The proarrhythmic incidence of many of these agents is not accurately known. In some instances, the facilitation of arrhythmias may be the result of compounding clinical factors. Many agents, however, share structural similarities to antiarrhythmics and manifest the same arrhythmic tendencies. Many reports of proarrhythmia may represent toxic rather than proarrhythmic effects, and in vitro studies to elicit the underlying mechanisms may be warranted for the more common drugs. This report summarizes reported arrhythmic effects of a variety of commonly utilized nonantiarrhythmic drugs. The incidence and mechanism of the proarrhythmia is not always clear. The clinician, however, should be aware of reported events to appropriately diagnose and treat the arrhythmia.

Anti-Bacterial Agents↗
PubMed1992

Hypothyroidism complicated by angina pectoris: therapeutic approaches.

The association of hypothyroidism and coronary artery disease is not uncommon. The precipitation of angina pectoris, cardiac arrhythmia, and even myocardial infarction may occur in patients when initiating rapid replacement therapy for hypothyroidism. This is particularly true when replacement therapy is instituted in elderly persons or in patients with preexisting coronary artery disease. A starting daily dose of 12.5 to 25 micrograms and increments of 25 micrograms every 2 to 3 weeks is recommended. Close monitoring of cardiac symptoms is essential to avoid side effects. Medical management of angina pectoris includes administration of beta-blockers, nitrates, or at times combination antianginal therapy may be most effective. Persistence of angina in these patients may require coronary angiography with subsequent angioplasty or coronary artery bypass surgery.

Adrenergic beta-Antagonists↗
PubMed1992

A comparison of tablets with oral suspension formulation of dipyridamole in thallium myocardial imaging.

Dipyridamole stress thallium imaging has been widely employed to diagnose and assess the extent of coronary heart disease in patients who cannot exercise. When oral dipyridamole administration was used, a wide range of results for sensitivity, specificity, hemodynamic response and side effect profile has been reported. The authors hypothesized that the formulation used for oral administration of dipyridamole plays a major factor in this variability, and that the pulverized form of dipyridamole will achieve faster and more consistent response than the standard tablet form. The authors studied 13 consecutive patients who underwent thallium scintigraphy. Eight patients received dipyridamole pulverized and dissolved in a glycol/aqueous base diluent (group A), and five patients received the standard form of dipyridamole (group B). In group A, mean peak systolic blood pressure decreased from 142 +/- 31 (mean +/- standard deviation) to 109 +/- 30 (P = .05), and mean diastolic blood pressure decreased from 76 +/- 14 to 51 +/- 5. The mean heart rate changed from 78 +/- 26 to 80 +/- 10. In group B, baseline systolic blood pressure was 165 +/- 12 and decreased to 156 +/- 7 at 45 minutes and to 155 +/- 14 at 90 minutes. Heart rate increased from baseline of 69 +/- 9 to 75 +/- 8 at 45 minutes and to 76 +/- 11 at 90 minutes. At 45 minutes, the systolic blood pressure of the 8 group A patients dropped by 33 +/- 19 mm Hg, whereas group B's changed by 9 +/- 6 mm Hg (P less than .005).(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗